EUVIMEDEUVIMED entdecken
Crossref

Macrophage-Targeted [ 11 C]DPA-713 PET/CT Imaging for Early Therapeutic Evaluation of Anti–Tumor Necrosis Factor Treatment in Rheumatoid Arthritis

Wouter Henk-Jan van Binsbergen, Jerney de Jongh, Maqsood Yaqub, Stéphanie van der Pas, Dirkjan van Schaardenburg, Alexandre E Voskuyl, Gerben J C Zwezerijnen, Conny J van der Laken

Journal of Nuclear Medicine · 2026-03 · 67 (3) · 456-462

DOI: 10.2967/jnumed.125.270289 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 30.12.2025. Verfasst von Wouter Henk-Jan van Binsbergen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, Amsterdam UMC, VUmc, Amsterdam, The Netherlands; w.h.vanbinsbergen@amsterdamumc.nl. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Positron Emission Tomography Computed Tomography, Pyrimidines, Pyrazoles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti-tumor necrosis factor (aTNF) treatment of rheumatoid arthritis (RA) requires 3-6 mo to establish efficacy, with 50%-70% response. Quantitative macrophage-targeting PET/CT previously proved to accurately represent RA activity and treatment response. This study investigated early aTNF treatment efficacy assessment using the [11C]N,N-diethyl-2-(4-methoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-acetamide ([11C]DPA-713) macrophage-targeting PET/CT tracer.

Methods

Two whole-body [11C]DPA-713 PET/CT scans, at baseline and 4 wk, were performed in 20 patients without exposure to biologic agents before starting aTNF treatment. Tracer uptake in joints was quantified by determination of SUVs in 44 joints at baseline and 4 wk of aTNF treatment. Mean SUVs of all joints and specific joint clusters were related to clinical evaluation of the 44 included joints for tenderness (tender joint count of 44 joints [TJC44]) and swelling (swollen joint count of 44 joints [SJC44]) at 26 wk using linear regression analyses. In addition, multivariable analysis, including both PET/CT and concurrent clinical outcome of independent measures versus dependent TJC44 or SJC44 at 26 wk, was performed.

Results

Univariate regression analyses showed significant associations between mean SUVpeak of all joints at baseline (TJC44, r 2 = 0.61; SJC44, r 2 = 0.50; P < 0.001) and 4 wk (TJC44, r 2 = 0.52; SJC44, r 2 = 0.48; P < 0.001) and TJC44 or SJC44 at 26 wk. For specific joint clusters, high correlations were found between SUVpeak of metacarpophalangeal joints at 4 wk and SUVpeak of SJC44 at 26 wk (r 2 = 0.67; P < 0.001). Multivariable analyses showed slightly increased correlations (r 2 ≤ 0.75) by combining PET/CT and TJC44, SJC44, and C-reactive protein measurements.

Conclusion

Early quantitative [11C]DPA-713 PET/CT measurements at baseline and 4 wk of aTNF treatment are associated with clinical disease activity at 26 wk. Therefore, quantitative macrophage [11C]DPA-713 PET/CT may have potential clinical value for early prediction of aTNF treatment response in patients with RA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidPositron Emission Tomography Computed TomographyPyrimidinesPyrazolesMacrophagesTumor Necrosis Factor-alphaHumansMaleFemaleMiddle AgedAgedCarbon RadioisotopesTreatment OutcomeAdultAcetamides

Stichwörter der Autor:innen

macrophage PET/CT imagingrheumatoid arthritistheranostics

Substanzen

PyrimidinesPyrazolesN,N-diethyl-2-(2-(4-methoxyphenyl)-5,7-dimethyl-pyrazolo(1,5-a)pyrimidin-3-yl)-acetamideCarbon RadioisotopesCarbon-11Tumor Necrosis Factor-alphaAcetamides

Autor:innen und Institutionen

  • Department of Rheumatology and Clinical Immunology, Amsterdam UMC, VUmc, Amsterdam, The Netherlands; w.h.vanbinsbergen@amsterdamumc.nl.
  • Department of Rheumatology and Clinical Immunology, Amsterdam UMC, VUmc, Amsterdam, The Netherlands.
  • Department of Radiology and Nuclear Medicine, Amsterdam UMC, VUmc, Amsterdam, The Netherlands.
  • Department of Epidemiology and Data Science, Amsterdam UMC, VUmc, Amsterdam, The Netherlands.
  • Methodology Section, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands; and.
  • Department of Rheumatology, Reade, Amsterdam, The Netherlands.

Zitieren

APA

van Binsbergen, W. H., de Jongh, J., Yaqub, M., van der Pas, S., van Schaardenburg, D., Voskuyl, A. E., Zwezerijnen, G. J. C., & van der Laken, C. J. (2026). Macrophage-Targeted [ 11 C]DPA-713 PET/CT Imaging for Early Therapeutic Evaluation of Anti–Tumor Necrosis Factor Treatment in Rheumatoid Arthritis. Journal of Nuclear Medicine, 67(3), 456-462. https://doi.org/10.2967/jnumed.125.270289

Vancouver

van Binsbergen WH, de Jongh J, Yaqub M, van der Pas S, van Schaardenburg D, Voskuyl AE, et al. Macrophage-Targeted [ 11 C]DPA-713 PET/CT Imaging for Early Therapeutic Evaluation of Anti–Tumor Necrosis Factor Treatment in Rheumatoid Arthritis. Journal of Nuclear Medicine. 2026;67(3):456-462. doi:10.2967/jnumed.125.270289

BibTeX
@article{vanBinsbergen2026,
  author = {van Binsbergen, Wouter Henk-Jan and de Jongh, Jerney and Yaqub, Maqsood and van der Pas, Stéphanie and van Schaardenburg, Dirkjan and Voskuyl, Alexandre E and Zwezerijnen, Gerben J C and van der Laken, Conny J},
  title = {Macrophage-Targeted [ 11 C]DPA-713 PET/CT Imaging for Early Therapeutic Evaluation of Anti–Tumor Necrosis Factor Treatment in Rheumatoid Arthritis},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  volume = {67},
  number = {3},
  pages = {456--462},
  doi = {10.2967/jnumed.125.270289}
}
Kostenlos starten →